



PRESS RELEASE

EDEN BIODESIGN AND THE UNIVERSITY OF MANCHESTER INTELLECTUAL PROPERTY LIMITED (UMIP) DEVELOP INNOVATIVE TREATMENT FOR CANCER

Liverpool, UK; 6th August 2007: Eden Biodesign Ltd, an expert provider of development and manufacturing services for new biopharmaceutical medicines, announced today that it has been selected by UMIP to provide a range of services for the development of a novel therapeutic for treatment of macular degeneration and cancer.

Professor Paul Bishop, School of Medicine, University of Manchester, who leads the team that discovered the new therapeutic, commented: "We are very pleased for this exiting programme to be further developed by Eden Biodesign. The experience of Eden Biodesign's management team in the development of biologics ensures that our programme will be well positioned for an accelerated clinical development and will increase the value of our programme to industrial partners."

"We look forward to helping UMIP and Professor Bishop to accelerate the transfer of this new therapy from research labs into clinical development", said Dr Crawford Brown, CEO of Eden Biodesign. "Eden Biodesign has the expertise in product development and manufacturing that is critical to ensure clinical and commercial success of this product."

Professor Paul Bishop has been awarded a grant from the National Biomanufacturing Centre (NBC) Access Fund administered by the Northwest Regional Development Agency (NWDA) towards the cost of the project. The project will be executed at the state of the art NBC, operated by Eden Biodesign and funded by NWDA, European Regional Development Fund (ERDF) and Department of Trade and Industry (DTI). "We are pleased that the NBC is able to provide practical help to Professor Paul Bishop and UMIP Ltd for the commercialisation of their discoveries which have the potential to offer both patient benefit and consolidation of the UK's lead in biopharmaceutical development in Europe" said Dr Linda Magee, NWDA Biotechnology Sector Director & Head of Bionow.

Dr Rich Ferrie, Head of BioMedica Operations at UMIP added, "This is the first of a number of our projects that should benefit from the excellent facilities at NBC and the product development expertise of Eden Biodesign. We believe that Opticin has tremendous therapeutic potential and the work package planned is an important next step in our strategy of partnering this programme."

Ends



For further information contact:

Stéphanie Monfront, DeFacto Communications Ltd +44 (0)20 7861 3838
Email s.monfront@defacto.com

Clare Coyne, Roland Dransfield PR +44 (0)161 236 1122
Email Clare.Coyne@rdpr.co.uk

Aeron Haworth (Faculty of Life Sciences), Media Relations, The University of Manchester +44 (0)161 275 8383
Email: aeron.haworth@manchester.ac.uk

Notes to editors:

Eden Biodesign

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides consultancy, development and manufacturing services to large pharmaceutical companies, biotech companies, charities and academic groups across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit www.edenbiodesign.com.

UMIP

The University of Manchester Intellectual Property Limited (UMIP) is the managing agent of The University of Manchester for intellectual property commercialisation. UMIP's role is to enhance the scale and quality of The University's intellectual property development and commercialisation activities. UMIP works in highly positive relationships with researchers, entrepreneurs, business people, professional advisers and investors to achieve its goals. As a successful company it employs modern management approaches to licensing, joint ventures, spin-out and spin-in enterprises. UMIP has a flexible and tailored approach to each commercial opportunity to ensure that the possibilities and benefits for intellectual property transfer to the market-place are maximised. For further information please visit www.umip.com/

The National Biomanufacturing Centre

The £34.25 million National Biomanufacturing Centre which was officially opened in November 2006, is a Government-funded initiative led by the Northwest Regional Development Agency (NWDA) additionally



funded through the European Regional Development Fund (ERDF) and the Department of Trade and Industry (DTI) and aims to establish England's Northwest as one of the foremost biomanufacturing centres in Europe.

The centre provides the expertise and facilities to support new and existing biotechnology companies, offering product development services designed to fill in the skill and resource gaps that exist within these organisations. It also provides training in biomanufacturing and analytical sciences, delivering the skilled workforce required to expand the UK biopharmaceutical sector.

There is also an Access Fund of nearly £3 million funded by the Department of Trade and Industry and the European Regional Development Fund, which is available to qualifying small-to-medium companies and academic groups in the biotechnology sector to assist them in purchasing development and clinical manufacturing services from the Centre. For further please visit www.biomanufacturing.co.uk